Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection. Issue 8 (30th May 2015)

• Record Type: Journal Article
• Authors: Mustanoja, Satu; Metso, Tiina M.; Putaala, Jukka; Heikkinen, Noora; Haapaniemi, Elena; Salonen, Oili; Tatlisumak, Turgut
• Is Part Of: Brain and behavior. Volume 5:Issue 8(2015:Aug.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-05-30
• Subjects: Neurology -- Periodicals; Neurosciences -- Periodicals; Psychology -- Periodicals; Psychiatry -- Periodicals; 616.8005
• DOI: 10.1002/brb3.349
• Languages: English
• ISSNs: 2162-3279

Abstract

<abstract abstract-type="main" id="brb3349-abs-0001"> <title>Abstract</title> <sec id="brb3349-sec-0001" sec-type="section"> <title>Background</title> <p>Cervical artery dissection (CeAD) patients with or without stroke are frequently treated with either antiplatelet agents or vitamin K antagonists (VKAs), but few data are reported on the use of nonvitamin K oral anticoagulants (NOACs).</p> </sec> <sec id="brb3349-sec-0002" sec-type="section"> <title>Methods</title> <p>Between November 2011 and January 2014, we recorded data from patients with a stroke due to vertebral (VAD) or internal carotid artery dissection (ICAD). Patients using oral anticoagulants were included in the study and were divided into two treatment groups: patients using NOACs and those using VKAs. Excellent outcome was defined on modified Rankin Scale (mRS) ≤1 at 6 months.</p> </sec> <sec id="brb3349-sec-0003" sec-type="section"> <title>Results</title> <p>Of 68 stroke patients (67% male; median age 45 [39–53]), six (8.8%; two with VAD and four with ICAD) were treated with NOACs: three with direct thrombin inhibitor dabigatran and three with direct factor Xa inhibitor rivaroxaban. National Institutes of Health Stroke Scale score at baseline was 4 (3–7) in the NOAC versus 2 (1–7) in the VKA groups. Complete recanalization at 6 months was seen in most patients in the NOAC (<italic>n</italic> = 5; 83%) and VKA (<italic>n</italic> = 34; 55%) groups. All the patients using NOACs had mRS ≤1 at 6 months and none had an intracerebral hemorrhage (ICH). In the VKA group most patients (<italic>n</italic> = 48; 77%) had mRS ≤1, one patient (1.7%) had an ICH and one died.</p> </sec> <sec id="brb3349-sec-0004" sec-type="section"> <title>Conclusions</title> <p>In this small, consecutive single‐center patient sample treating ischemic stroke patients with CeAD with NOACs did not bring up safety concerns and resulted in similar, good outcomes compared to patients using VKAs.</p> </sec> </abstract>